514 related articles for article (PubMed ID: 23247983)
1. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy.
Hartwig W; Strobel O; Hinz U; Fritz S; Hackert T; Roth C; Büchler MW; Werner J
Ann Surg Oncol; 2013 Jul; 20(7):2188-96. PubMed ID: 23247983
[TBL] [Abstract][Full Text] [Related]
2. Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma.
Berger AC; Meszoely IM; Ross EA; Watson JC; Hoffman JP
Ann Surg Oncol; 2004 Jul; 11(7):644-9. PubMed ID: 15197014
[TBL] [Abstract][Full Text] [Related]
3. Increased levels of both carbohydrate antigen 19-9 and duke pancreatic monoclonal antigen type 2 reflect postoperative prognosis in patients with pancreatic carcinoma.
Shibata K; Iwaki K; Kai S; Ohta M; Kitano S
Pancreas; 2009 Aug; 38(6):619-24. PubMed ID: 19436235
[TBL] [Abstract][Full Text] [Related]
4. Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma?
Kim YC; Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI; Shin JH
J Gastroenterol Hepatol; 2009 Dec; 24(12):1869-75. PubMed ID: 19686409
[TBL] [Abstract][Full Text] [Related]
5. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9.
Koopmann J; Rosenzweig CN; Zhang Z; Canto MI; Brown DA; Hunter M; Yeo C; Chan DW; Breit SN; Goggins M
Clin Cancer Res; 2006 Jan; 12(2):442-6. PubMed ID: 16428484
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer.
Kondo N; Murakami Y; Uemura K; Hayashidani Y; Sudo T; Hashimoto Y; Nakashima A; Sakabe R; Shigemoto N; Kato Y; Ohge H; Sueda T
Ann Surg Oncol; 2010 Sep; 17(9):2321-9. PubMed ID: 20336387
[TBL] [Abstract][Full Text] [Related]
7. Preoperative CA 19-9 kinetics as a prognostic variable in radiographically resectable pancreatic adenocarcinoma.
Brown EG; Canter RJ; Bold RJ
J Surg Oncol; 2015 Mar; 111(3):293-8. PubMed ID: 25330934
[TBL] [Abstract][Full Text] [Related]
8. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma.
Fujioka S; Misawa T; Okamoto T; Gocho T; Futagawa Y; Ishida Y; Yanaga K
J Hepatobiliary Pancreat Surg; 2007; 14(6):539-44. PubMed ID: 18040617
[TBL] [Abstract][Full Text] [Related]
9. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
10. Utility of tumor markers in determining resectability of pancreatic cancer.
Schlieman MG; Ho HS; Bold RJ
Arch Surg; 2003 Sep; 138(9):951-5; discussion 955-6. PubMed ID: 12963650
[TBL] [Abstract][Full Text] [Related]
11. The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer.
Kinsella TJ; Seo Y; Willis J; Stellato TA; Siegel CT; Harpp D; Willson JK; Gibbons J; Sanabria JR; Hardacre JM; Schulak JP
Am J Clin Oncol; 2008 Oct; 31(5):446-53. PubMed ID: 18838880
[TBL] [Abstract][Full Text] [Related]
12. Clinical value of serum neopterin, tissue polypeptide-specific antigen and CA19-9 levels in differential diagnosis between pancreatic cancer and chronic pancreatitis.
Talar-Wojnarowska R; Gasiorowska A; Olakowski M; Lekstan A; Lampe P; Malecka-Panas E
Pancreatology; 2010; 10(6):689-94. PubMed ID: 21242708
[TBL] [Abstract][Full Text] [Related]
13. CEACAM1, a novel serum biomarker for pancreatic cancer.
Simeone DM; Ji B; Banerjee M; Arumugam T; Li D; Anderson MA; Bamberger AM; Greenson J; Brand RE; Ramachandran V; Logsdon CD
Pancreas; 2007 May; 34(4):436-43. PubMed ID: 17446843
[TBL] [Abstract][Full Text] [Related]
14. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.
Xu HX; Liu L; Xiang JF; Wang WQ; Qi ZH; Wu CT; Liu C; Long J; Xu J; Ni QX; Yu XJ
Surgery; 2017 Feb; 161(2):373-384. PubMed ID: 27838102
[TBL] [Abstract][Full Text] [Related]
15. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study.
Dong Q; Yang XH; Zhang Y; Jing W; Zheng LQ; Liu YP; Qu XJ
World J Surg Oncol; 2014 Jun; 12():171. PubMed ID: 24890327
[TBL] [Abstract][Full Text] [Related]
16. Preoperative serum CA19-9 and dissected peripancreatic tissue margin as determiners of long-term survival in pancreatic cancer.
Waraya M; Yamashita K; Katagiri H; Ishii K; Takahashi Y; Furuta K; Watanabe M
Ann Surg Oncol; 2009 May; 16(5):1231-40. PubMed ID: 19263172
[TBL] [Abstract][Full Text] [Related]
17. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma.
Ferrone CR; Finkelstein DM; Thayer SP; Muzikansky A; Fernandez-delCastillo C; Warshaw AL
J Clin Oncol; 2006 Jun; 24(18):2897-902. PubMed ID: 16782929
[TBL] [Abstract][Full Text] [Related]
18. Serum CA19-9 is a significant predictor among preoperative parameters for early recurrence after resection of pancreatic adenocarcinoma.
Sugiura T; Uesaka K; Kanemoto H; Mizuno T; Sasaki K; Furukawa H; Matsunaga K; Maeda A
J Gastrointest Surg; 2012 May; 16(5):977-85. PubMed ID: 22411488
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of serum D-dimer, fibrinogen, and CA19-9 for postoperative monitoring and survival prediction in resectable pancreatic carcinoma.
Cao J; Fu Z; Gao L; Wang X; Cheng S; Wang X; Ren H
World J Surg Oncol; 2017 Feb; 15(1):48. PubMed ID: 28219450
[TBL] [Abstract][Full Text] [Related]
20. CA19-9 capability as predictor of pancreatic cancer resectability in a Spanish cohort.
Herreros-Villanueva M; Ruiz-Rebollo L; Montes M; Rodriguez-Lopez M; Francisco M; Cubiella J; Iyo E; Garabitos E; Martínez Moneo E; Martos M; de Madaria E; Martínez-Arránz I; García-Cougil M; Iglesias-Gómez A; Bujanda L
Mol Biol Rep; 2020 Mar; 47(3):1583-1588. PubMed ID: 31915999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
